

STIMULAN[®]

Case study

Courtesy of Dr. Christopher P Demas

Professor and Chief, Albuquerque, NM, USA

Clinical particulars

69-year-old male presented with a complex history of his left ankle. The patient was initially treated for a left closed pilon fracture of the distal tibia with open reduction internal fixation. Over the following 13 years, the patient underwent ankle fusion, medial plantar island flap reconstruction due to wound breakdown and several treatments for wound dehiscence. After an occurrence of wound dehiscence about the medial aspect of the ankle, the patient was hospitalised, an I&D was performed and cultures tested positive for MRSA. The patient underwent weekly wound care visits with daily packing changes at home.

In total, the patient endured fifteen surgeries prior to presenting with chronic draining sinus. He was hospitalised and cultures tested positive for *Serratia*.

Treatment

Debridement of scarred skin, deep tissue and bone within the chronic osteomyelitis cavity was carried out to remove all non-viable tissue. **STIMULAN** mixed with antibiotic was injected as a paste to fill the resulting dead space. The cavity was covered with a reverse sural flap and I.V. antibiotics were administered to treat the infection.

Outcome

The patient underwent debridement satisfactorily with partial absorption of **STIMULAN** paste at 3 months. The patient was fully healed and free from infection 14 months after treatment, and remains infection free 2 years after treatment.



Presentation



Pre-operative



3 months



14 months

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time, absorption characteristics and/or bone formation. It is the surgeon/healthcare professional's responsibility to give due consideration to the details in the medicinal product marketing authorisation in deciding whether it is appropriate for the patient under his/her care. The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of medicinal substance should also be assessed according to the individual patient's clinical circumstance.

This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2020, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 88883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US 10390954
Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A